The pregnane X receptor (PXR) has been well-established as a critical mediator in regulating important drug metabolizing enzymes and transporter proteins, including cytochrome P450 3A4 (CYP3A4) and Pglycoprotein (P-gp). Previous studies identified that PXR served as a molecular target of SUMOylation. However, the impact of SUMOylation of PXR on its transcriptional activity in regulating the expression/ activity of the target genes is poorly investigated. In the current study, we established cell-based models of SUMOylated PXR in LS174T cells to investigate the impact of SUMOylation of PXR on regulating the expression/activity of CYP3A4 and P-gp. Our results revealed that rifampicin-induced PXR transactivation of the CYP3A4 and P-gp promoter was suppressed by SUMOylation of PXR in reporter gene assay. The mRNA and protein expression of CYP3A4 and P-gp was also suppressed. Moreover, CYP3A4 enzymatic assay and Rho123 intracellular assay revealed that rifampicin-induced CYP3A4 and P-gp activity was also suppressed by SUMOylated PXR. Our data collectively indicated for the first time that SUMOylation of PXR exerts suppressive effect on rifampicin-induced expression and activity of CYP3A4 and P-gp, which suggest that alteration in the SUMOylation status of PXR will be expected to affect the CYP3A4 mediated drug metabolism and P-gp mediated drug transport.
Drugedrug interactions (DDIs) have been identified as an important clinical issue which cause change in systemic exposure of drugs by other co-administered medication. A number of these interactions are due to alterations in expression and activity of drug metabolizing enzymes and transporter proteins, among which cytochrome P450 3A4 (CYP3A4) and P-glycoprotein (P-gp) gained the most investigation (1) . CYP3A4, one of the major isozyme of CYPs in humans, is abundantly expressed in liver and intestine. It has broad substrate specificity responsible for biotransformation of over 50% of all clinically prescribed drugs (2) . P-gp, encoded by the MDR1 gene in humans, belongs to the ATP-binding cassette (ABC) superfamily. It is expressed in many tissues, including gastrointestinal epithelium and canalicular membrane of the liver (3) . P-gp is responsible for the efflux of xenobiotics from cells and therefore plays a key role in influencing the pharmacokinetics of numerous drugs (4) . Alteration in the expression and activity of CYP3A4 or/ and P-gp may change the exposure and affect the response of many administered drugs in patients (5) .
The pregnane X receptor (PXR, NR1I2), predominately expressed in liver and intestine, belongs to the superfamily of ligand-activated transcriptional factors. To date, PXR has been wellestablished as a critical mediator in regulating important drug metabolizing enzymes (DMEs) and transporter proteins, including ABBREVIATIONS: SUMO, small ubiquitin-related modifier; PXR, pregnane X receptor; RIF, rifampicin; CYP3A4, cytochrome P450 3A4; P-gp, p-glycoprotein; MDZ, midazolam; 1 0 -OHMDZ, 1 0 -Hydroxymidazolam; Rh123, rhodamine 123.
CYP3A4 and P-gp (6) . For example, PXR-mediated gene activation may lead to profound up-regulation of CYP3A4 and/or P-gpmediated metabolism, transport, and elimination of potentially toxic compounds from the body, and thus result in potential DDIs (7) . Recent studies have indicated an emerging role for posttranslational modification of PXR in regulating multiple biochemical pathways, including ubiquitylation, phosphorylation, acetylation, and SUMOylation (8) . SUMOylation is mediated by Small Ubiquitin-like Modifiers (SUMO) which can be covalently attached to a broad range of substrate proteins in eukaryotic cells. SUMOylation regulates various cellular functions including proteineprotein interaction, sub-cellular localization, regulation of DNA binding, etc (9) . The human genome contains three functional genes that encode SUMO proteins called SUMO-1, SUMO-2, and SUMO-3. The SUMO pathway constitutes a conserved enzymatic cascade which is initiated by an ATP-dependent activation of the SUMO protein by a SUMO-activating enzyme (also called E1). The activated SUMO protein is then transferred to a SUMO-conjugating enzyme (E2 ligase) called Ubc9. Finally, the SUMO protein is further transferred from Ubc9 to the lysine residue within the substrate with the assistance of one of the several E3 SUMO protein ligases (10, 11) . SUMOylation of several nuclear receptors (NRs) such as peroxisome proliferator-activated receptor a (PPARa), liver X receptor b (LXRb), and retinoid-related orphan receptor a (RORa) has been demonstrated to play critical roles in modulating their function. Specifically, SUMOylation of NRs displays repression on their transcriptional activity while some potentiate their transcriptional activation, suggesting another perspective of the NR-mediated regulation of their target genes (12e14). Most recently, it has been reported that PXR could be SUMOylated via Ubc9 as E2 conjugating enzyme and PIAS4 as E3 ligases (8, 15) . Therefore, it is of particular interest to determine whether the transcriptional activity of PXR and regulation of the expression/activity of its target genes such as CYP3A4 and P-gp could be changed by SUMOylation.
In the current study, we transiently transfected PXR and SUMOrelated plasmids in LS174T cells to establish cell-based models of SUMOylated PXR to study the impact of SUMOylation of PXR on regulating the expression/activity of CYP3A4 and P-gp. Our data revealed that SUMOylated PXR suppressed the RIF-induced transcriptional activation and expression of CYP3A4 and P-gp. In addition, RIF-induced CYP3A4 and P-gp activity was also suppressed by SUMOylation of PXR.
Materials and methods

Chemicals and reagents
The pSG5-hPXR expression vector was provided by Dr. Steven Kliewer (University of Texas Southwestern Medical Center, Dallas, TX) (16) . The pGL3-CYP3A4-XREM luciferase reporter construct (17), pcDNA3-6His-SUMO3, plasmids p3258 (pCMV-hUBC9), and pcDNA4-hismax-PIAS4 were provided by Dr. Jeff Staudinger (University of Kansas, Lawrence, KS). The tk-MDR1-Luc was from Dr. Wen Xie (University of Pittsburgh, Pittsburgh, PA). The pRL-TK Renilla luciferease control vector was obtained from Promega (Madison, WI). Rifampicin (RIF) and dimethyl sulphoxide (DMSO) were purchased from SigmaeAldrich (St. Louis, MO). All other chemicals and solvents were commercially available and of analytical grade.
Cell culture
LS174T cells (derived from Caucasian colon adenocarcinoma) were purchased from Shanghai Institute for Biological Sciences cell resource center (Shanghai, China) and maintained in RPMI 1640 medium (Hyclone, Logan, UT, USA) supplemented with 10% FBS. Both cell lines were cultured at 37 C under a humidified atmosphere of 5% CO 2 .
Cell-based SUMOylation assays
The cell-based SUMOylation assays were performed using a previously described method with slight modification (15) . Briefly, LS174T cells were grown for 24 h until 90% confluence. Cells were transfected with pSG5-hPXR, pcDNA3-6His-SUMO3, pCMV-hUBC9, and pcDNA4-hismax-PIAS4 using Lipofectamine 2000 (Invitrogen) according to the manufacturer's instructions. pcDNA3.1þ were added as empty vectors. 48 h after transfection, cells were washed with phosphate-buffered saline (PBS) and harvested in lysis buffer (6 M guanidinium-HCl, 10 mM Tris, 100 mM sodium phosphate buffer, pH 8.0). After sonication, the cell lysates were mixed with Ni 2þ -linked agarose (QIAGEN). The mixture was incubated for 2 h on a rotator at room temperature and centrifuged to gather the beads. The beads were then washed in wash buffer I (8 M urea, 10 mM Tris, and 100 mM sodium phosphate buffer, pH 8.0), II (8 M urea, 10 mM Tris, 100 mM sodium phosphate buffer, pH 6.3, 0.1% Triton X-100, and 5 mM b-mercaptoethanol), III (150 mM NaCl, 10 mM imidazole, and 50 mM sodium phosphate buffer, pH 6.75), and PBS. The beads were then resuspended in 2*SDS-PAGE gel loading buffer and samples were resolved on 10% SDS-PAGE for Western blot analysis to detect the SUMOylated form of PXR using the H-11 monoclonal anti-PXR antibody (Santa Cruz). measured by a Dual Reporter Assay System (Promega). Transfection efficiency was determined by Renilla luciferase activity, and the firefly luciferase activity was determined and normalized against Renilla luciferase activity.
Transient transfection and reporter gene analysis
Total RNA isolation and quantitative real-time polymerase chain reaction analysis (qPCR)
Total RNA was isolated from LS174T cells using Trizol reagent (Invitrogen, Grand Island, NY). After DNase I treatment, RNA was reversely transcribed into cDNA using the PrimeScript™ RT reagent Kit (Takara, Kyoto, Japan). Equal amounts of cDNA were used in real-time quantitative polymerase chain reactions (rt-QPCRs). The sequences (5 0 to 3 0 ) for the primers are as follows: CYP3A4, forward primer (TCAGCCTGGTGCTCCTCTATCTAT), reverse primer (AAGCCCTTATGGTAGGACAAAATATTT); P-gp, forward primer (CCATAGCTCGTGCCCTTGTTAGA), reverse primer (CGGTGAGCAAT-CACAATGCAG); and GAPDH (human), forward primer (GGATTTGGTCGTATTGGG), reverse primer (GGAA-GATGGTGATGGGATT). RT-QPCR was performed using a SYBR Premix Ex Taq II (Tli RnaseH Plus) kit (TaKaRa Biotech) in an Applied Biosystems 7500 Real-Time PCR System (Applied Biosystems, Foster City, CA). Cycling conditions were 95 C for 30s followed by 40 cycles of 95 C for 5 s, 60 C for 20 s, and 40 C for 60 s. The fold induction was calculated as described previously (18).
Western blotting analysis
Western blot analysis was performed as described previously (19) . Briefly, transfected LS174T cells were incubated with DMSO (0.1%) or Rifampicin (10 mM) for 48 h. Protein extracted from cells was then prepared using RIPA lysis buffer containing EDTA and protease inhibitors, and quantified by BCA protein assay (Thermo Scientific, Rockford, IL). Protein samples were then separated on 8%e12% SDS-PAGE and electrophoretically transferred onto polyvinylidene fluoride membranes (Millipore, Bedford, USA) that were probed with primary antibodies including CYP3A4 (SC-53850), Pgp (SC-13131) (Santa Cruz Biotechnology) and GAPDH (14C10) (Cell Signaling Technology). Immunodetection was performed using an enhanced chemiluminescence (ECL) detection kit (Engreen Biosystem, Beijing, China) and analyzed using the ImageJ software (National Institute of Health, Bethesda, MD).
CYP3A4 enzymatic assay
Transfected LS174T cells were treated with 0.1% DMSO or 10 mM RIF for 48 h. The culture medium was then removed, replaced with medium containing midazolam (MDZ) (40 mM) and cultured for additional 4 h. Subsequently, tert-butyl methyl ether/dichloromethane (75:25, v/v), ammonia/water (1:30, v/v), and digitoxin (3 mg/ml) as the internal standard (IS) were added to the cells with culture medium for liquideliquid extraction. The metabolite was extracted by centrifugation. The supernatant was then evaporated and the residue was dissolved in methanol/H 2 O (containing 5 mM ammonium formate and 0.1% formic acid) (8:2, v/v). The activity of CYP3A4 was measured by the formation of 1 0 -hydroxymidazolam (1 0 -OHMDZ) using a previously described LC-MS/MS method with slight modification (20, 21) . Briefly, the samples were analyzed using Ultimate 3000 UPLC system (Dionex Corporation, Sunnyvale, CA) interfaced with triple quadrupole mass spectrometer (TSQ Quantum Access, Thermo Fisher Scientific, Waltham, MA). Chromatographic separations were performed on an XTerra MS C18 column (50 mm Â 2.1 mm, i.d., 3.5 mm, Waters) at room temperature. The samples were eluted with methanol/H 2 O (8:2, v/v) at a flow rate of 0.2 ml/min. The total running time was 3.0 min for each sample. Electrospray positive ionization mode (ESI þ ) was used for 1 0 -OHMDZ analysis. Selective reaction monitoring (SRM) experiments using m/z 342.02 / 168.01 and 782.67 / 635.24 was performed to monitor and quantitate 1 0 -OHMDZ and IS, respectively.
Rho123 intracellular assay
Transfected LS174T cells were incubated with DMSO (0.1%) or Rifampicin (10 mM) for 48 h. 2 mg/ml of Rh123 was then added to the cells, which were incubated in the dark at 37 C under a humidified atmosphere of 5% CO 2 for additional 1 h. To measure the intracellular accumulation of Rh123, the mean fluorescence intensity (MFI) associated with Rh123 was determined by Monochromators Based Multimode Microplate Reader with excitation/ emission wavelengths of 485/535 nm.
Statistical analysis
Data are presented as the mean ± SEM and expressed as fold change over the DMSO treated group transfected with empty vector. One-way analysis of variance (ANOVA) was performed for statistical comparison of the results, which was followed by LSD-t test using GraphPad Prism (GraphPad Software Inc., San Diego, CA). The criterion of significance was set at P < 0.05 (*P < 0.05, **P < 0.01, ***P < 0.001).
Results
3.1. SUMOylation of PXR suppressed RIF-induced PXR transactivation of the CYP3A4 and P-gp promoter in reporter gene transfected cells First, we confirmed that PXR could be SUMOylated by SUMO3 with the assistance of Ubc9 as E2 conjugating enzyme and PIAS4 as E3 ligases in cell-based assay (Fig. 1) . Dual-luciferase reporter assays were then used to evaluate the effect of SUMOylation on PXR transactivation of the CYP3A4 or P-gp promoter in reporter gene transfected LS174T cells. As shown in Fig. 2 , treatment with RIF in PXR-overexpressed cells largely induced the reporter activities of CYP3A4-luc ( Fig. 2A ) and MDR1-luc (Fig. 2B ) when compared to those of the DMSO treated cells, indicating the successfully construction of models for assessing PXR transactivation. The reporter activity was not affected by over-expression of SUMO cascade (SUMO3, UBC9, and PIAS4) alone. However, over-expressing SUMO cascade significantly suppressed the RIF-induced CYP3A4 and P-gp reporter activities in PXR-transfected cells. These results indicated that SUMOylation of PXR exhibits suppressive effect on RIF-induced PXR transactivation of CYP3A4 and P-gp promoter.
SUMOylation of PXR suppressed the RIF-induced mRNA and protein expression of CYP3A4 and P-gp
To investigate whether the suppressive effect of SUMOylated PXR was also exerted on RIF-induced gene expression of CYP3A4 and P-gp, the mRNA levels of CYP3A4 and P-gp in transfected LS174T cells were measured by qPCR. As expected, treatment with RIF markedly induced the mRNA expression of CYP3A4 (19.13 ± 5.02 Fig. 1 . Detection of SUMOylated PXR protein in LS174T cells. LS174T cells were transfected with different expression vectors as indicated in Materials and methods. Cells were lysed using denaturing buffer containing guanidinium hydrochloride to inactivate de-SUMOylation enzymes. SUMOylated proteins were purified by using nickellinked agarose beads. The blot was probed for PXR immunoreactivity using a monoclonal antibody that recognizes the human PXR protein.
fold) and P-gp (5.67 ± 2.11 fold) when compared to those of the DMSO treated PXR-overexpressed cells. A statistically significant decrease in the RIF-induced CYP3A4 (P < 0.01) and P-gp (P < 0.05) mRNA level was observed when SUMO cascade was co-expressed in the PXR-overexpressed cells (Fig. 3A and B) . We next examined the protein level of CYP3A4 and P-gp in transfected LS174T cells using Western blot analysis. Protein expression of both CYP3A4 and P-gp was induced by RIF treatment in PXR-overexpressed cells. A statistically significant decrease in the RIF-induced CYP3A4 and P-gp protein levels (P < 0.05) was observed when SUMO cascade was co-expressed ( Fig. 3C and D) . Taking together, in addition to the promoter activity, SUMOylation of PXR also suppressed RIF-induced gene and protein expression of CYP3A4 and P-gp.
SUMOylation of PXR suppressed the RIF-induced activity of CYP3A4 and P-gp
As SUMOylation of PXR suppresses RIF-induced expression of CYP3A4 and P-gp on gene and protein level, it is interesting to know whether the CYP3A4 enzymatic activity and P-gp transporter activity are also affected. The CYP3A4 enzymatic activity was determined by measuring the formation of 1'-hydroxymidazolam (1 0 -OHMDZ), the metabolite of typical CYP3A4 substrate midazolam in Materials and methods. Cells were treated with DMSO (0.1%) or RIF (10 mM) for 24 h or 48 h, and then CYP3A4 and P-gp mRNA (AeB) or protein (CeD) levels were analyzed. Data are expressed as fold change over the DMSO treated group transfected with empty vector. P values (*P < 0.05, **P < 0.01, ***P < 0.001) indicate statistically significant when RIFtreated cells in PXR þ SUMO-transfected group were compared to RIF-treated cells in PXR-transfected group (n ¼ 3).
(MDZ). As shown in Fig. 4A and B, PXR-overexpressed cells treated with RIF yielded 2.02 ± 0.40 fold of 1 0 -OHMDZ compared to that in DMSO treated PXR-overexpressed cells, which was consistent with the expression level of CYP3A4. A statistically significant decrease in the RIF-induced CYP3A4 (P < 0.01) enzymatic activity level was observed when SUMO cascade was co-expressed in the PXRoverexpressed cells.
To determine whether P-gp activity was also decreased after SUMOylation of PXR, we conducted accumulation experiment by recruiting fluorescent dye Rh123, a specific substrate of P-gp. PXRoverexpressed cells treated with RIF resulted in 34.19 ± 11.14% decrease of intercellular Rho123 compared to that in DMSO treated PXR-overexpressed cells, whereas only 13.45 ± 9.73% decrease of intercellular Rho123 could be observed when SUMO cascade was co-expressed in the PXR-overexpressed cells (Fig. 4C) . Taken together, these results were generally consistent with those observed in the reporter assay, qPCR and Western blot.
Discussion
Increasing evidences have implicated that drugedrug interactions or multidrug resistance related to loss of drug therapeutic efficacy or safety are caused by PXR-mediated transactivation of diverse drug-metabolizing enzymes or drug transporters (22) . CYP3A4 and P-gp, both of which are wellcharacterized PXR target genes, represent the two most important determinants responsible for the unfavorable DDIs or even fatal adverse drug reactions. Therefore, evaluation of regulatory factors involved in altering PXR transcriptional activity of CYP3A4 and P-gp has evolved to be extremely important. The mechanism underlying PXR transactivation of CYP3A4 and P-gp involves ligand binding to PXR which in turn results in binding to the response element within the promoter of a target gene. The process requires heterodimerization between PXR and retinoid X receptor (RXR) for high-affinity DNA binding (23) .
In addition to the well-characterized prototypical ligandmediated transcriptional activation of PXR, recent study revealed that PXR undergoes SUMOylation by incorporation of SUMO3 chains to repress inflammatory response. However, the effect of SUMO modification on PXR-target gene activation and subsequent biochemical functions are still largely unknown. It has been reported that the transcriptional activity of key members of the nuclear receptor superfamily were changed upon SUMOylation (12, 13) . For example, SUMOylation of PPARa had a negative effect on its transcription activity through selective recruitment of corepressor NcoR (12) . Zhang et al. showed that SUMO modification could impair LXRb binding to its target DNA sequence, which may serve as a possible mechanism for the suppressive effect on LXRmediated gene activation. Specifically, SUMO cascades decreased the abundance of LXRb bound to the Srebp1c promoter containing LXR response element, thereby suppressing its transactivation of target genes (14) . Nevertheless, data from luciferase reporter gene assay suggested that overexpression of SUMO3 and Ubc9 had no impact on PXR transactivation in CV-1 cells (15), which was contrary to our results of the current study.
In our study, we transiently transfected PXR and SUMO cascaderelated plasmids including SUMO3, UBC9, and PIAS4 in LS174T cells for studying the impact of SUMOylation on PXR transcriptional activity. We first confirmed that PXR could be SUMOylated by SUMO3 with the assistance of Ubc9 and PIAS4 in cell-based assay. It was interesting to notice that PXR without SUMOylation could also be detected with PXR antibody in Western blotting. As PXR protein contains two zinc finger motifs, and zinc and nickel share similar properties as metals, it is possible that nickel in affinity columns mimics the zinc and interact with PXR proteins. We then investigated the role of SUMO modification in PXR transactivational activity of CYP3A4 and MDR1 by using a luciferase reporter gene assay. We found that overexpression of SUMO3, UBC9, and PIAS4 can significantly suppress the PXR-mediated RIF-induced CYP3A4 and MDR1 reporter activity. Previous studies indicated that UBC9, the only E2 enzyme identified, is sufficient for covalent attachment of SUMO to specific substrates in vitro. However, E3 ligases are still essential for protein SUMOylation, which may particularly enhance the efficiency and selectivity of SUMO attachment to target substrates (24e26). It is noteworthy that members of Protein Inhibitor of Activated STAT (PIAS) family are known SUMO E3 ligases with the RING finger domain indispensable for its activity (25) . In addition to PIAS family proteins, other structurally different types of RING-containing proteins also exhibit E3 ligase activity in SUMOylation reactions, which may provide a possible illustration for various SUMOylation status of specific substrates in different cells. A study pioneered by Dahle et al. indicated that enhancing SUMOylation by cotransfection of PIAS4 suppressed both basal and Myb-induced level of reporter activation. The basal level of SUMOylation in CV-1 cells was significantly enhanced by overexpression of PIAS4 when compared to that without PIAS4 (26) . Therefore, PIAS4 may increase the SUMOylation of PXR, in which way that the suppressive effect of SUMOylation on PXR-mediated gene activation could be observed in our study. Next, we employed qPCR, Western blot analysis, and activity assay for CYP3A4 and P-gp, to verify the suppressive effect of SUMOylated PXR on RIF-inducible expression and activity of CYP3A4 and P-gp.
Based on the well-described characteristics of PXR transcriptional activation of CYP3A4 and P-gp, further studies could be conducted to elucidate the potential molecular mechanisms underlying the suppressive effect of SUMOylated PXR on its function. The attachment of SUMO protein to the lysine residues within PXR may interfere the binding of ligands to the ligand-binding domain (LBD) of the receptor, and possibly increase the strength of interaction between PXR and the co-repressor proteins such as nuclear receptor co-repressor (NCoR), while inhibit the recruitment of coactivator proteins such as steroid receptor co-activators (SRC1 and SRC2). Moreover, SUMOylation may alter the PXR activity by disrupting the heterodimerization with retinoid X receptor a (RXRa) and subsequent binding to the responsive element in the promoter of the target genes. Nevertheless, experimental animals can also be employed as useful in vivo models for future research in addition to immortalized cell lines.
A number of studies in experimental animals have shown that systemic inflammation and acute infection are capable of downregulating the activities and/or expression of drug-metabolizing enzymes (27, 28) . Pronounced changes in the expression of ABC transporters including P-gp have also been reported in classic models of the inflammatory response (29e31). As activation of inflammation strongly promotes the SUMOylation statues of PXR (15) , it is of particular interest to reveal whether SUMOylated PXR acts as the molecular basis underlying the suppression of DMEs and transporter proteins in response to inflammation. In the current study, we identified that SUMOylation of PXR suppresses the RIFinduced expression and activity of CYP3A4 and P-gp, which may provide a plausible mechanism for down-regulated expression and/or activities of DMEs and transporter proteins under inflammation.
In summary, our results revealed for the first time the suppressive effects of SUMOylated PXR on the RIF-induced expression and activity of CYP3A4 and P-gp. Therefore, alteration in the SUMOylation status of PXR will be expected to affect the CYP3A4 mediated drug metabolism and P-gp mediated drug transport.
